Bank of New York Mellon Corp Buys 399,041 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Bank of New York Mellon Corp boosted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 3,160.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 411,667 shares of the company's stock after acquiring an additional 399,041 shares during the period. Bank of New York Mellon Corp owned 0.33% of Atossa Therapeutics worth $490,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cetera Advisors LLC purchased a new position in shares of Atossa Therapeutics during the first quarter worth about $72,000. Vanguard Group Inc. grew its stake in Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock worth $10,357,000 after buying an additional 78,269 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Atossa Therapeutics in the 1st quarter worth $151,000. Institutional investors own 12.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ATOS shares. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Atossa Therapeutics in a report on Monday, August 12th. StockNews.com lowered Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, August 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th. Finally, Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a "buy" rating in a research note on Wednesday, September 11th.

Atossa Therapeutics Stock Performance

NASDAQ ATOS traded down $0.01 during trading on Wednesday, hitting $1.39. 267,673 shares of the company's stock traded hands, compared to its average volume of 1,179,214. The stock has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.42. Atossa Therapeutics, Inc. has a 12-month low of $0.62 and a 12-month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities analysts forecast that Atossa Therapeutics, Inc. will post -0.22 EPS for the current year.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.